258 related articles for article (PubMed ID: 18090663)
1. Role of the endocannabinoid system in metabolic control.
Wang J; Ueda N
Curr Opin Nephrol Hypertens; 2008 Jan; 17(1):1-10. PubMed ID: 18090663
[TBL] [Abstract][Full Text] [Related]
2. The endocannabinoid system: a new target for the regulation of energy balance and metabolism.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):46-50. PubMed ID: 17667864
[TBL] [Abstract][Full Text] [Related]
3. [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].
Sulcová A
Vnitr Lek; 2006 Jun; 52(6):615-8. PubMed ID: 16871766
[TBL] [Abstract][Full Text] [Related]
4. The endocannabinoid system: a promising target for the management of type 2 diabetes.
Scheen AJ
Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.
Vemuri VK; Janero DR; Makriyannis A
Physiol Behav; 2008 Mar; 93(4-5):671-86. PubMed ID: 18155257
[TBL] [Abstract][Full Text] [Related]
6. The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.
Kyrou I; Valsamakis G; Tsigos C
Ann N Y Acad Sci; 2006 Nov; 1083():270-305. PubMed ID: 17148745
[TBL] [Abstract][Full Text] [Related]
7. The endocannabinoid system as a novel approach for managing obesity.
Lillo JL
J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
[TBL] [Abstract][Full Text] [Related]
8. [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].
Bramlage P; Böcking W; Kirch W
Dtsch Med Wochenschr; 2005 Mar; 130(12):665-8. PubMed ID: 15776349
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoid system and cardio-metabolic risk.
Loh KY; Kew ST
Med J Malaysia; 2008 Oct; 63(4):348-50; quiz 351. PubMed ID: 19385504
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid control of food intake and energy balance.
Di Marzo V; Matias I
Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of cannabinoid receptors and glucose metabolism.
Scheen AJ; Paquot N
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):505-11. PubMed ID: 18542014
[TBL] [Abstract][Full Text] [Related]
13. Role of the endocannabinoid system in energy balance regulation and obesity.
Cota D
Front Horm Res; 2008; 36():135-145. PubMed ID: 18230900
[TBL] [Abstract][Full Text] [Related]
14. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
Wierzbicki AS
Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
[TBL] [Abstract][Full Text] [Related]
15. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu J; Sternon J
J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.
Deedwania P
Int J Cardiol; 2009 Jan; 131(3):305-12. PubMed ID: 18715660
[TBL] [Abstract][Full Text] [Related]
17. [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation].
Kvasnicka T
Cas Lek Cesk; 2005; 144(2):81-4; discussion 85. PubMed ID: 15807291
[TBL] [Abstract][Full Text] [Related]
18. Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.
Bennetzen MF
Dan Med Bull; 2011 Apr; 58(4):B4269. PubMed ID: 21466769
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.
Woods SC
JAAPA; 2007 Nov; Suppl Endocannabinoid():7-10. PubMed ID: 18047036
[TBL] [Abstract][Full Text] [Related]
20. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]